CN1440785A - Composite medicine for treating throat diseases - Google Patents
Composite medicine for treating throat diseases Download PDFInfo
- Publication number
- CN1440785A CN1440785A CN03111902A CN03111902A CN1440785A CN 1440785 A CN1440785 A CN 1440785A CN 03111902 A CN03111902 A CN 03111902A CN 03111902 A CN03111902 A CN 03111902A CN 1440785 A CN1440785 A CN 1440785A
- Authority
- CN
- China
- Prior art keywords
- medicine
- present
- catechu
- treatment
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention belongs to one composite Chinese medicine for treating throat diseases. The Chinese medicine is prepared with bezoar, catechu, myrrh, dragon's blood, pearl and other four kinds of Chinese medicinal materials and through conventional preparation process. It may be medicine powder, tablet or drilling pills and its medicine reaches the affected part to result in high curative effect and less side effect. It may be used in treating several kinds of throat diseases.
Description
(1) described technical field
The invention belongs to a kind of pharmaceutical composition for the treatment of laryngopharyngeal diseases, particularly a kind of pure Chinese medicine medicine for the treatment of laryngopharyngeal diseases.
(2) background technology
At present, along with the continuous deterioration of environment and warming of terrestrial climate, and various viruses is popular, and people suffer from the more and more of laryngopharyngeal diseases.This disease mainly shows as aphtha of the mouth and tongue, swelling and sore throat, oral ulcer, oral cavity infantile eczema, pharyngitis, laryngitis, makes an indiscreet remark and give birth to oral cavity and throat diseases such as mute.But at present, also do not have specific medicine to treat, particularly utilize Chinese medicine to carry out this respect treatment still less.
(3) summary of the invention
The object of the present invention is to provide laryngopharyngeal diseasess such as a kind of treatment pharyngitis, laryngitis, oral ulcer disease, have good effect, effect is fast, the pure Chinese medicinal preparation that side effect is little.
The object of the present invention is achieved like this:
The invention discloses a kind of pharmaceutical composition for the treatment of laryngopharyngeal diseases, is by following materials of weight proportions, the powder that method is routinely made
Calculus Bovis 5-10g Moschus 3-5g catechu 15-20g Olibanum 20-30g
Myrrha 20-30g Sanguis Draxonis 10-20g Margarita 7-8g Indigo Naturalis 50-100g
Borneolum Syntheticum 30-35g Pulvis Talci 40-50g
The pharmaceutical composition of treatment laryngopharyngeal diseases of the present invention, the better weight proportion of described raw material is
Calculus Bovis 6-8g Moschus 4-5g catechu 16-19g Olibanum 22-28g
Myrrha 22-28g Sanguis Draxonis 12-18g Margarita 7-8g Indigo Naturalis 60-80g
Borneolum Syntheticum 30-35g Pulvis Talci 40-50g
The pharmaceutical composition of treatment laryngopharyngeal diseases of the present invention, described medicine method is routinely made tablet or containing drop pill.One. following is the pharmacology pharmacodynamic research of medicine of the present invention
According to medicine of the present invention, function cures mainly, and chooses the positive contrast medicine of pills for throat disease.Carry out following pharmacodynamics test altogether:
1 medicine analgesic activity of the present invention
1. medicine Dichlorodiphenyl Acetate of the present invention causes the analgesic activity of pain mice, the result shows: what the large, medium and small dosage group of medicine of the present invention can reduce significantly all that acetic acid causes the pain mice turns round the body number of times, with the ordinary water group than P＜0.05, illustrate that medicine of the present invention has analgesic activity preferably.
2. medicine of the present invention is to the analgesic activity of hot plate mice, and the result shows: the heavy dose of group of medicine of the present invention all can significantly improve hot plate mice threshold value in 0.5 and 1 hour behind medicine, with the ordinary water group than P＜0.05, with positive group than P＜0.05.
2 medicine antiinflammatory actions of the present invention
1. medicine of the present invention is to the influence of mice capillary permeability, and the result shows that medicine small dose group of the present invention has significant inhibitory effect to the mice capillary permeability, compares P＜0.05 with the ordinary water group.
2. medicine of the present invention is to the influence of mice auricle swelling, and the result shows, the big or middle dosage group of medicine of the present invention all can highly significant suppresses the mice auricle swelling that caused by dimethylbenzene, with the ordinary water group than P＜0.01; Its big or middle dosage group has antiinflammatory action preferably.
3. medicine of the present invention is to the bullate influence of rat granuloma, and the result shows: big or middle dosage group of medicine of the present invention and ordinary water group comparison rat granuloma swell remarkable inhibitory action (P＜0.01, P＜0.05) are all arranged; Strong (P＜0.05=illustrates that medicine of the present invention also has antiinflammatory action preferably to chronic inflammatory disease to heavy dose of group than positive drug group to the bullate inhibitory action of rat granuloma.
The bacteriostatic experiment of 3 medicines of the present invention
1. the external bacteriostatic experiment of medicine of the present invention
The result shows that medicine of the present invention is 10mg/ml to the Mlc of staphylococcus aureus and dust Xi Shi bacillus; Staphylococcus aureus there is stronger bactericidal action.
2. bacteriostatic experiment in the medicine body of the present invention
The result shows, compares with the ordinary water group, and medicine of the present invention has significant endogenous protective effect to the mice of staphylococcus aureus, coli-infection.
More than test shows: medicine of the present invention has obvious anti-inflammatory and analgesic effect, to the auricular concha swelling of mice dimethylbenzene and rat granuloma are swollen remarkable inhibitory action is arranged, and the mice capillary permeability is had remarkable inhibitory action; Hot plate is caused pain mice and acetic acid to be caused and turns round the body mice remarkable analgesic activity is arranged; Antibacterial action is preferably arranged, and the inside and outside bacteriostatic experiment shows that escherichia coli and staphylococcus aureus are all had bacteriostasis preferably.Above result is the basis of its performance clinical efficacy.
Two. toxicological test
1 medicine animal acute toxicity test research of the present invention
The mice maximum dosage-feeding is 240g/kg, is 300 times of the clinical consumption of people.Observed 7 days behind the mouse stomach, do not see death and other abnormal phenomenas, body weight gain is normal, and appetite is good.Put to death after 7 days, the ANOMALOUS VARIATIONS of internal organs is not seen in perusal yet, and the overt toxicity reaction does not appear in mice, and it is safe pointing out clinical use.
2 medicine rat long term toxicity test researchs of the present invention
This experimental observation the long term toxicity of three months (12 week) of medicine continuous irrigation stomach of the present invention to rat.Get 160 of healthy Wistar rats, male and female half and half, be divided into four groups of (dosage group, medicine small dose group of the present invention in matched group, the heavy dose of group of medicine of the present invention, the medicine of the present invention) every morning gastric infusions at random by body weight, administration is 7 days weekly, 12 weeks of successive administration, situations such as outward appearance of perusal every day animal and general behavior and appetite, defecation.Regularly weigh in, carry out hematology and blood biochemical and learn inspection.And 60 days, 90 days, 120 days (convalescent period) of open medicine animal is cutd open inspection, taking internal organ is weighed and is carried out histopathological examination.Result of the test shows, rat successive administration 90 days, every indexs such as each administration group rats eating, movable normal, body weight all have growth in various degree before than administration, and the hematology detects, blood biochemical is learned detections and organ coefficient and matched group compare no significant difference (P＞0.05).Internal organs such as each administration treated animal heart of histopathologic examination, liver, spleen, lung, kidney, stomach, thymus, adrenal gland, uterus, ovary, testis, prostate and matched group relatively there is no obvious pathomorphology and change.
Medicine of the present invention cures mainly aphtha of the mouth and tongue, swelling and sore throat, and oral ulcer, the oral cavity infantile eczema, pharyngitis, laryngitis is made an indiscreet remark and is given birth to diseases such as mute.
The function of medicine of the present invention is a putrefaction-removing granulation-promoting, and hemostasis relieves the pain, invigorating blood circulation what, the function of heat-clearing and toxic substances removing.
Medicine of the present invention is powder, tablet or containing drop pill, and its drug effect directly arrives the affected part, good effect, and effect is fast, and side effect is little, can treat the multiple disease of throat, is pure Chinese medicinal preparation.
(4) specific embodiment
1. example 1
Get the raw material of following weight,
Calculus Bovis 10g Moschus 5g catechu 20g Olibanum 20g
Myrrha 20g Sanguis Draxonis 10g Margarita 7g Indigo Naturalis 50g
Borneolum Syntheticum 35g Pulvis Talci 50g
Above raw material is ground, sieve, make powder.
Using method: powder of the present invention is sprayed on site of disease in the oral cavity, 0.1-0.4g/ time, every day 3-6 time.
2. example 2
Get following materials of weight proportions,
Calculus Bovis 5g Moschus 3g catechu 15g Olibanum 30g
Myrrha 30g Sanguis Draxonis 20g Margarita 8g Indigo Naturalis 100g
Borneolum Syntheticum 30g Pulvis Talci 40g
Above raw material is ground, sieve, make powder.
Using method: powder of the present invention is sprayed on site of disease in the oral cavity, 0.1-0.4g/ time, every day 3-6 time.
3. example 3
Get following weight proportion raw material,
Calculus Bovis 8g Moschus 4g catechu 17g Olibanum 25g
Myrrha 25g Sanguis Draxonis 15g Margarita 8g Indigo Naturalis 80g
Borneolum Syntheticum 33g Pulvis Talci 45g
Above raw material is ground, sieve, make powder.
Using method: powder of the present invention is sprayed on site of disease in the oral cavity, 0.1-0.4g/ time, every day 3-6 time.
4. example 4
Get following materials of weight proportions,
Calculus Bovis 7g Moschus 5g catechu 18g Olibanum 24g
Myrrha 25g Sanguis Draxonis 15g Margarita 7g Indigo Naturalis 60g
Borneolum Syntheticum 35g Pulvis Talci 40g
Above raw material is ground, sieve, add a small amount of amylum pregelatinisatum, make tablet, every sheet 4g.
Using method: 1 slice/time, containing, every day 3-6 time.
Claims (3)
1. pharmaceutical composition for the treatment of laryngopharyngeal diseases is characterized in that: be by following materials of weight proportions, and the powder that method is routinely made
Calculus Bovis 5-10g Moschus 3-5g catechu 15-20g Olibanum 20-30g
Myrrha 20-30g Sanguis Draxonis 10-20g Margarita 7-8g Indigo Naturalis 50-100g
Borneolum Syntheticum 30-35g Pulvis Talci 40-50g
2. the pharmaceutical composition of treatment laryngopharyngeal diseases according to claim 1 is characterized in that: described raw material weight proportioning is
Calculus Bovis 6-8g Moschus 4-5g catechu 16-19g Olibanum 22-28g
Myrrha 22-28g Sanguis Draxonis 12-18g Margarita 7-8g Indigo Naturalis 60-80g
Borneolum Syntheticum 30-35g Pulvis Talci 40-50g
3. the pharmaceutical composition of treatment laryngopharyngeal diseases according to claim 1 and 2 is characterized in that: described medicine method is routinely made tablet or containing drop pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031119026A CN1290549C (en) | 2003-02-26 | 2003-02-26 | Composite medicine for treating throat diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031119026A CN1290549C (en) | 2003-02-26 | 2003-02-26 | Composite medicine for treating throat diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1440785A true CN1440785A (en) | 2003-09-10 |
| CN1290549C CN1290549C (en) | 2006-12-20 |
Family
ID=27770294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031119026A Expired - Fee Related CN1290549C (en) | 2003-02-26 | 2003-02-26 | Composite medicine for treating throat diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1290549C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772648A (en) * | 2012-07-10 | 2012-11-14 | 于传伍 | Traditional Chinese medicine composition for curing oral ulcer |
| CN103494984A (en) * | 2013-09-26 | 2014-01-08 | 苏福松 | Traditional Chinese medicine for treating goat oral cavity ulceration and preparation method thereof |
-
2003
- 2003-02-26 CN CNB031119026A patent/CN1290549C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772648A (en) * | 2012-07-10 | 2012-11-14 | 于传伍 | Traditional Chinese medicine composition for curing oral ulcer |
| CN103494984A (en) * | 2013-09-26 | 2014-01-08 | 苏福松 | Traditional Chinese medicine for treating goat oral cavity ulceration and preparation method thereof |
| CN103494984B (en) * | 2013-09-26 | 2016-02-10 | 苏福松 | A kind of Chinese medicine for the treatment of goat oral cavity ulceration and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1290549C (en) | 2006-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102885856B (en) | Production method for producing medicine for treating hepatitis B by periplaneta americana extract | |
| Gumel et al. | Biogenic synthesis of silver nanoparticles and its synergistic antimicrobial potency: An overview | |
| CN103211801A (en) | Film agent quickly dissolved in oral cavity and preparation method thereof | |
| CN1290549C (en) | Composite medicine for treating throat diseases | |
| AU2011296641B2 (en) | Antifungal composition | |
| CN1615889A (en) | Medicine for treating skin disease | |
| CN111388500A (en) | Pharmaceutical composition for oral mucosa ulcer inflammatory pain and bacteriostasis, gel and preparation method thereof | |
| CN1251738C (en) | Chinese medicine for treating ashen nail and its preparation method | |
| Bae et al. | Polysaccharides isolated from Phellinus gilvus enhances dermal wound healing in streptozotocin-induced diabetic rats | |
| CN103393778B (en) | Compound Chinese herbal preparation for preventing and treating fish bacteria and viral diseases | |
| CN1915369A (en) | Pill for treating whitish and turbid urine of women fungal leucorrhea of dedicatedly | |
| CN1742875A (en) | Anti-inflammation medicine of Jindenglong on changbaishan mountain and preparation method | |
| CN106389454A (en) | Compound erythromycin thiocyanate soluble powder for livestock and preparation method therefor | |
| KR101965591B1 (en) | Composition for inhibiting activity of amylase containing chitooligosaccharide | |
| CN1278443A (en) | Medicine for treating disease of upper respiratory tract and its preparation | |
| CN101254288A (en) | Applications of Chinese medicinal composition for curing colpitis medicament | |
| CN1372930A (en) | Application of N-acetyl-D-aminoglucose in preparing medicines to prevent and treat sexual disfunction | |
| CN101044882A (en) | Mineral feed additive for prevention and control of fowl influenza | |
| CN1299649A (en) | External-use medicine for dermatosis and its preparation | |
| ES2369138T3 (en) | COMPOSITIONS FOR VETERINARY AND MEDICAL APPLICATIONS. | |
| CN109646456A (en) | It is a kind of for treating the new type gel of periodontitis | |
| CN1233313C (en) | Gel agent for treating acne and its preparation method | |
| CN1049099A (en) | Compound xidi iodine sucked tablet and preparation method thereof | |
| CN1839882A (en) | Medicament composition for treating tinea pedis and tinea corporis | |
| CN100394967C (en) | Chinese medicine composition for treating wrinary tract disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061220 |